Sun Pharma is an Indian pharmaceutical company that was founded by Dilip Shanghvi in 1983. It is headquartered in Mumbai, Maharashtra.
It manufactures as well as sells APIs (Active Pharmaceutical Ingredients) in India as well as US.It started in Vapi with 5 products that treated Psychiatry ailments. In 1987, cardiology products were introduced and after that in 1989, Gastroenterology products were introduced.
Today Sun Pharma is the market leader in Psychiatry, Cardiology, Ophthalmology, Neurology, Gastroenterology and Nephrology.
Sun Pharma has a drug named Synriam that is very effective in treating Malaria which is one of the most common infectious diseases in the world and also provide ARV (Anti-Retroviral) therapy which helps in fighting the war against AIDS.
Sun Pharma acquired Ranbaxy Laboratories in 2015 which is one of the biggest acquisitions ever in the Pharmaceutical industry and became the largest pharmaceutical company in India and 5th largest in the world. It also acquired GSK’s Opiates business in Australia the same year. Its state-of-the-art manufacturing facilities are located in five continents and around 150 countries majorly in India, US, Canada, Ireland, South Africa, Malaysia and Mexico.
Sun Pharma sees value when it invests in its Research and Development and thus invests heavily in order to upgrade its technology and make robust products for diverse markets. Its R&D expenditure was around 860 crores in FY15-16.
Sun Pharma always focus on quality in all its operations be it testing, manufacturing or R&D of its pharmaceutical products. This year in 2016, Sun Pharma is set to launch its eye-care drug named BromSite which had already been approved by US FDA in April.